TGTPG GP A, LLC

Institutional investor · Portfolio as of Q4 2025

Top Holdings10 positions

Checking export access…
Activity:

LIFESTANCE HEALTH GROUP INC

160.7M$1.1B42.1%$9.52-26.05%
17 qtrssince 2021-Q4
Unchanged
0

LIFE TIME GROUP HOLDINGS INC

17.8M$473.9M17.6%$17.21+54.45%
17 qtrssince 2021-Q4
Unchanged
0

BETA TECHNOLOGIES INC

16.4M$462.5M17.2%$28.050.00%
1 qtr
New
100

SIONNA THERAPEUTICS INC

6.7M$277.5M10.3%$11.60+256.87%
4 qtrssince 2025-Q1
Unchanged
0

AMNEAL PHARMACEUTICALS INC

12.3M$155.3M5.8%$4.79+163.05%
17 qtrssince 2021-Q4
Unchanged
0

CERIBELL INC

4M$87M3.2%$25.86-16.05%
5 qtrssince 2024-Q4
Unchanged
0

BICARA THERAPEUTICS INC

3M$50.7M1.9%$25.44-36.64%
6 qtrssince 2024-Q3
Unchanged
0

ALLOGENE THERAPEUTICS INC

18.7M$25.6M1.0%$15.38-91.48%
17 qtrssince 2021-Q4
Unchanged
0
TRTXTRTX
REIT

TPG RE FINANCE TRUST INC

2.4M$20.6M0.8%$6.94+12.70%
17 qtrssince 2021-Q4
Unchanged
0

RALLYBIO CORP

3M$2.1M0.1%$77.60—
17 qtrssince 2021-Q4
Unchanged
0
$2.7B
AUM
10
Positions
Q4 2025
Filing
HI score · 1.0/5
Quarterly 13F Value Change
-9%Q3'24$5.9B+6%Q4'24$6.2B-20%Q1'25$5B-62%Q2'25$1.9B-2%Q3'25$1.8B+46%Q4'25$2.7B
Activity profile
$ moved · Q4'25
New100%Increased0%Decreased0%Exited0%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.7 years
<1Q10%1-4Q10%1-2Y20%2Y+60%

TPG GP A, LLC manages $2.7B across 10 positions as of Q4 2025. Top holdings: LFST (42.1%), LTH (17.6%), BETA (17.2%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.

Q4 2025 Summary

Added 1 new position. Top move: BETA (NEW, conviction 100). Portfolio: $2.7B across 10 positions.

Top holdings by portfolio weight

Total AUM$3B
LFST42.11%
LTH17.64%
BETA17.21%
SION10.33%
AMRX5.78%
CBLL3.24%
BCAX1.89%
ALLO0.95%
TRTX0.77%
RLYB0.08%

Portfolio allocation by GICS sector

Sectors4
Healthcare64.38%
Consumer Cyclical17.64%
Industrials17.22%
Real Estate0.77%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Healthcare, Consumer Cyclical, Industrials
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&LNo data
Conviction42
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used